On day 4, cells were resuspended in fresh selection media (RPMI 1640 with 2mM L-glutamine (Gibco), 5% FBS (Gibco), 1x Antibiotic/Antimycotic (Gibco), 5 g/ml Blasticidin (Gibco), and 0.5 g/ml Puromycin (Gibco))
Humans only produce alpha-lipoic acid in small amounts
Tissue sections were observed under a Leica DMI-3000B microscope (Leica, Germany)
There was marked immune cell enrichment, predominately T cells, monocytes, and natural killer cells
Specific GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) have demonstrated cardiovascular benefits in clinical trials, including reduced risk of major adverse cardiovascular events
This discrepancy results in questions about semaglutide compounding